Skip to main
FEMY
FEMY logo

Femasys (FEMY) Stock Forecast & Price Target

Femasys (FEMY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Femasys Inc's strategic partnerships with established distributors enhance its market presence and customer familiarity, which is expected to bolster sales for its product offerings, particularly FemaSeed. The positive relationships with these distributors are set to play a crucial role in the planned commercialization of FemBloc, further strengthening the company's growth trajectory. Additionally, Femasys anticipates the potential to start recognizing sales for FemBloc in Europe as early as the second half of 2025 or the first half of 2026, indicating a promising outlook for revenue expansion in international markets.

Bears say

Femasys Inc faces significant risks that contribute to a negative outlook on its stock, particularly concerning the potential emergence of safety signals in its clinical or preclinical programs and the risk of lower-than-expected efficacy in its clinical trials. Additionally, strong competition in the marketplace from existing and developing treatments poses a threat to the company's product offerings, which may further hinder commercial success. The financial health of Femasys is also a concern, as it is projected to require approximately $60 million in additional financing through 2038, with the current cash runway expected to last only until mid-2025.

Femasys (FEMY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Femasys and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Femasys (FEMY) Forecast

Analysts have given Femasys (FEMY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Femasys (FEMY) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Femasys (FEMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.